ASHP therapeutic position statement on strategies for identifying and preventing pneumococcal resistance.
The incidence of drug-resistant S. pneumoniae continues to increase, causing significant morbidity and mortality. Health care providers should seize the opportunity to promote the judicious use of antimicrobials and aggressive vaccination with the pneumococcal vaccines as a means to lessen this significant health problem.
Billeter
Marianne
M
D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial / Q000235:genetics / Q000502:physiology; D006801:Humans; D010593:Pharmaceutical Services / Q000592:standards*; D010607:Pharmacy Service, Hospital / Q000592:standards; D011008:Pneumococcal Infections / Q000188:drug therapy / Q000517:prevention & control; D022242:Pneumococcal Vaccines; D012955:Societies, Medical; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000276:immunology; D014481:United States
D000900:Anti-Bacterial Agents; D022242:Pneumococcal Vaccines